Skip to main content

Aggressive Breast Cancer Responds to New Drug

By
woman looking at mamagram image

In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.



from WebMD Health https://ift.tt/2EnqLcY
via IFTTT
Labels:

Comments

Post a Comment

Popular posts from this blog

The Future of Autoimmune Disorders: Psoriatic Disease

By
What's being done to help people with psoriatic disease? We get a look at the ever-changing picture from a rheumatologist. from WebMD Health https://ift.tt/5P6ZHyd via IFTTT
Post a Comment
Read more

Long COVID Experts: ‘So Incredibly Clear What’s at Stake’

By
It’s estimated that more than a third of people who have had COVID-19 experience neurological complications such as brain fog that persist or develop 3 months after infection. And two thirds of so-called long haulers still have neurological symptoms after 6 months. from WebMD Health https://ift.tt/mx1j6QD via IFTTT
Post a Comment
Read more

Study: Black Men Twice as Likely to Develop Prostate Cancer as Whites

By
A review of men seen at VA hospitals found that Black veterans had nearly twice the incidence of localized and advanced prostate cancer as white men. from WebMD Health https://ift.tt/3Knscs2 via IFTTT
Post a Comment
Read more